Psychedeic-Chronicle-Logo

Suggestions

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS

Psychedeic-Chronicle-Logo

Psychedelic News - Page 2

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment Psychedeic-Chronicle-Logo-White
Psychedelic News

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

October 10, 2022

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced today that it has begun a preclinical toxicity study of its novel time-released, dosage-controlled ketamine formulation, designated as SP-26, for the treatment of fibromyalgia. About Silo Pharma Silo Pharma is a biotechnology startup that

Read More
Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use Psychedeic-Chronicle-Logo-White
Psychedelic News

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

October 7, 2022

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus Bioscience, recently announced the development of a tea bag containing psilocybin for use in clinical research. If granted appropriate regulatory approvals, this could eventually be used as a treatment for clients in psychedelic-assisted therapy. Numinus strives to be at the cutting edge of psychedelic-assisted therapies

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial Psychedeic-Chronicle-Logo-White
October 7, 2022

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic DMT drug

Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio Psychedeic-Chronicle-Logo-White
September 30, 2022

Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio

Recently, clinical-stage psychedelic biotechnology company Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

Small-Pharma-Receive-UK-Regulatory-Approval-to-Begin-DMT-Assisted-Psychotherapy-and-SSRI-Drug-Interaction-Study Psychedeic-Chronicle-Logo-White
Psychedelic News

Small Pharma Receive UK Regulatory Approval to Begin DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

Psychedelic biotechnology company Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) announced today confirmation of regulatory approval from the U.K. Medicines and Healthcare

August 15, 2022
Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia Psychedeic-Chronicle-Logo-White
Psychedelic News

Short Wave Pharma Sign Clinical Trial Agreement with Sheba Research Fund & Sheba Center for Eating Disorders to Study Psilocybin Treatment for Anorexia

Biopharmaceutical company Short Wave Pharma Inc. has announced a signed Clinical Trial Agreement with the Sheba Fund for Health Services and Research. Dr. Eitan

August 15, 2022
Field-Trip-Health-Wellness-Announce-19-Million-Financing-To-Trade-on-TSXV-Under-Ticker-FTHW Psychedeic-Chronicle-Logo-White
Psychedelic News

Field Trip Health & Wellness Announce $19.9 Million Financing, Will Trade on TSXV Under Ticker FTHW

Field Trip Health & Wellness Ltd. announced today that the company has filed the necessary listing application to list its common shares

August 15, 2022
Silo-Pharma-Announce-Topically-Administered-Ketamine-Delivers-Positive-Results-in-Study Psychedeic-Chronicle-Logo-White
Psychedelic News

Silo Pharma Announce Topically Administered Ketamine Delivers Positive Results in Study

Silo Pharma, Inc. (OTCQB: SILO), a development-stage psychedelic biopharmaceutical firm, announced that the company’s patented topically applied ketamine formulation has completed a

August 2, 2022
Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials Psychedeic-Chronicle-Logo-White
Psychedelic News

Biomind Labs Hire Former FDA Director To Oversee Psychedelic Drug Development Clinical Trials

World-class psychedelic biotech firm Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) announced that Former FDA Director Dr. Thomas Laughren has

August 1, 2022
Filament Health Join TheraPsil in Worlds Largest Medical Psilocybin Access and Data Project Psychedeic-Chronicle-Logo-White
Psychedelic News

Filament Health Join TheraPsil in World’s Largest Medical Psilocybin Access and Data Project

Clinical‐stage natural psychedelic drug development company Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) today announced the company’s participation in Project Solace, the

July 28, 2022
Wellbeing KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex Psychedeic-Chronicle-Logo-White
Psychedelic News

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into

July 22, 2022
Journey-Colab-Announces-Appointment-of-Joel-A-Posener-MD-as-Chief-Medical-Officer Psychedeic-Chronicle-Logo-White
Psychedelic News

Journey Colab Announces Appointment of Joel A. Posener, MD as Chief Medical Officer

Biopharmaceutical company Journey Colab who are working to unlock the science of psychedelics and build a new model for addiction treatment recently

July 20, 2022
MAPS-Launches-Online-Education-Curriculum-Psychedelic-Fundamentals Psychedeic-Chronicle-Logo-White
Psychedelic News

MAPS Launches New Online Education Curriculum ‘Psychedelic Fundamentals’

The first part in the new MAPS Digital Learning initiative is Psychedelic Fundamentals, which introduces those interested in learning to the fundamental

July 15, 2022
Zylorion Announces New U.S. Patent Filing For Novel Second-Generation Psilocybin-Based Compound Psychedeic-Chronicle-Logo-White
Psychedelic News

Zylorion Announces New U.S. Patent Filing For Novel Second-Generation Psilocybin-Based Compound

Zylorion announced today the filing of the Company’s third provisional patent application with the United States Patent and Trademark Office (“USPTO”). The

July 14, 2022
Previous 1 2 3 Next

Recent Posts

  • Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment
  • Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use
  • atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial
  • Tryp Therapeutics Add 2 New Provisional Patents to Intellectual Property Portfolio
  • Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression

Recent Comments

No comments to show.

Popular

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Silo Pharma (Nasdaq: SILO), a developmental-stage psychedelic biopharmaceutical firm, announced

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Develop Psilocybin Mushroom Tea Bags for Psychedelic Research Use

Numinus Wellness Inc.’s (OTCQX: NUMIF) (TSX: NUMI) research division, Numinus

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai Life Sciences Announce First Subject Dosed in Synthetic DMT Phase 1 Trial

atai has administered the first dosage of their VLS-01 synthetic

Psychedeic-Chronicle-Logo

© 2022 PSYCHEDELIC CHRONICLE
ALL RIGHTS RESERVED.

  • Psychedelic News
  • DMT
  • Ketamine
  • Mescaline
  • Psilocybin
  • CEO INTERVIEWS